Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: Quantification using a multi-type mathematical model

Vaccine

Volumn 30, Issue 23, 2012, Pages 3383-3388

  Choi, Yoon Hong ^a   Chapman, Ruth ^a   Gay, Nigel ^b   Jit, Mark ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Fu Consulting   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Human papillomavirus; Individual based model; Mathematical model; Unmasking; Vaccine

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER INCIDENCE; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FEMALE; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING; STOCHASTIC MODEL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS TRANSMISSION; VIRUS TYPING; WART VIRUS;

ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84859873329     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.065     Document Type: Article

References (24)

1. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O-E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. The Journal of Infectious Diseases 2009, 199(April (7)):926-935.
2. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 2012, 13(Jan (1)):89-99.
3. Beutels P., Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sexual Health 2010, 7(September (3)):352-358.
4. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet 2007, 369(June (9580)):2161-2170.
5. Wheeler C.M. Less is more: a step in the right direction for human papillomavirus (HPV) vaccine implementation. Journal of the National Cancer Institute 2011, 103(September (19)):1424-1425.
6. Wentzensen N., Schiffman M., Dunn T., Zuna R.E., Gold M.A., Allen R.A., et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Journal international du cancer[[n1]]International Journal of Cancer 2009, 125(November (9)):2151-2158.
7. Quint W., Molijn A., Colau B., van de Sandt M., Jenkins D. One HPV virus, one lesion as determined by LCM/PCR technology. 25th international papillomavirus conference 2009, Abstract 06.04.
8. Lipsitch M. Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. American Journal of Epidemiology 2001, 154(July (1)):85-92.
9. Frazão N., Sá-Leão R., de Lencastre H. Impact of a single dose of the 7-valent pneumococcal conjugate vaccine on colonization. Vaccine 2010, 28(April (19)):3445-3452.
10. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343(September (1)). p. d5775-d5775.
11. Jit M., Gay N., Soldan K., Choi Y.H., Edmunds W.J. Estimating progression rates for human papillomavirus infection from epidemiological data. Medical Decision Making 2010, 30(1):84-98.
12. Choi Y.H., Jit M., Gay N., Cox A., Garnett G.P., Edmunds W.J. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28(May (24)):4091-4102.
13. Howell-Jones R., Bailey A., Beddows S., Sargent A., de Silva N., Wilson G., et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. British Journal of Cancer 2010, 103(July (2)):209-216.
14. Crowder M.J., Tredger J.A. The use of exponentially damped polynomials for biological recovery data. Journal of the Royal Statistical Society. Series C (Applied Statistics) 1981, 30(2):147-152.
15. Brisson M., Van de Velde N., Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12(January (5-6)):343-351.
16. Van de Velde N., Brisson M., Boily M-C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(July (33)):5473-5484.
17. van Doorn L-J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. Journal of Clinical Microbiology 2006, 44(September (9)):3292-3298.
18. Mori S., Nakao S., Kukimoto I., Kusumoto-Matsuo R., Kondo K., Kanda T. Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Science 2011, 102(June (6)):1223-1227.
19. Eklund C., Zhou T., Dillner J. Global proficiency study of human papillomavirus genotyping. Journal of Clinical Microbiology 2010, 48(November (11)):4147-4155.
20. Tjalma W., Paavonen J., Naud P., Wheeler C., Chow S.-N., Apter D., et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naive population. Presentation at the 16th international meeting of the European society for gynaecological oncology. International Journal of Gynecological Cancer 2009, 19(Suppl. 2):1446.
21. Elbasha E.H., Galvani A.P. Vaccination against multiple HPV types. Mathematical Biosciences 2005, 197(September (1)):88-117.
22. Poolman E.M., Elbasha E.H., Galvani A.P. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine 2008, 26(July):C25-30.
23. Mejlehede N., Pederson B.V., Frisch M., Fomsgaard A. Multiple human papilloma virus types in cervical infections: competition or synergy?. APMIS 2010, 118(May (5)):346-352.
24. Thomas K.K., Hughes J.P., Kuypers J.M., Kiviat N.B., Lee S.K., Adam D.E., et al. Concurrent and sequential acquisition of different genital human papillomavirus types. The Journal of Infectious Diseases 2000, 182(October (4)):1097-1102.